Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

This trial is testing a combination of two immunotherapy drugs — iparomlimab and tuvonralimab — together with low-dose radiation and chemotherapy in people with locally advanced head and neck squamous cell carcinoma (cancer in the mouth, throat, or nearby structures that has not yet spread to distant parts of the body). The study aims to see if this combination improves outcomes compared to standard treatment. **You may be eligible if:** - You are between 18 and 75 years old - You have been diagnosed with Stage III–IVB head and neck squamous cell carcinoma (confirmed by biopsy) - You have not received any prior treatment for this cancer (no chemotherapy, targeted therapy, or immunotherapy) - You are in good functional health (ECOG performance status 0 or 1) - You have adequate blood counts and organ function **You may NOT be eligible if:** - You have active autoimmune disease requiring treatment, or another condition that could be worsened by immunotherapy - You have untreated or uncontrolled thyroid disease, severe infections, or active hepatitis - You have received prior immunotherapy or chemotherapy for this cancer - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.